Literature DB >> 16417225

Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model.

Miyo Aoki-Ota1, Mari Kinoshita, Takayuki Ota, Kazuyuki Tsunoda, Toshiro Iwasaki, Sigeru Tanaka, Shigeo Koyasu, Takeji Nishikawa, Masayuki Amagai.   

Abstract

Pemphigus vulgaris (PV) is an autoimmune blistering disease caused by IgG autoantibodies against desmoglein 3 (Dsg3). We have recently developed an active disease mouse model for PV by adoptive transfer of splenocytes from Dsg3(-/-) mice. The purpose of this study was to determine the role of CD40/CD154 interaction in the pathogenic antibody production and development of the disease in PV model mice. When anti-CD154 monoclonal antibody (mAb) was administered to recipient mice prior to adoptive transfer, anti-CD154 mAb almost completely blocked the anti-Dsg3 IgG production and prevented blister formation. The blockade of CD40/CD154 interaction induced tolerance against Dsg3 as the suppression of antibody production was observed through day 70, and it was maintained even after challenge by immunization with recombinant mouse Dsg3 or by adoptive transfer of immunized Dsg3(-/-) splenocytes. Furthermore, the tolerance to Dsg3 was transferable because cotransfer of splenocytes from anti-CD154 mAb-treated mice and naïve Dsg3(-/-) splenocytes significantly suppressed anti-Dsg3 IgG production in recipient mice. In contrast, when anti-CD154 mAb was injected after the mice had developed the PV phenotype, no significant suppression of the production of anti-Dsg3 IgG was observed. These findings indicate that the CD40/CD154 interaction is essential for the induction of pathogenic anti-Dsg3 IgG antibodies and that antigen-specific immune-regulatory cells induced by anti-CD154 mAb would hold a therapeutic option for autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16417225     DOI: 10.1038/sj.jid.5700016

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  13 in total

1.  Distinct strategies are required to suppress antigen-specific responses to genetically modified keratinocytes and fibroblasts.

Authors:  Soosan Ghazizadeh; Li T Huang; Weibing Zhang
Journal:  Mol Ther       Date:  2011-10-11       Impact factor: 11.454

Review 2.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 3.  Seeking approval: present and future therapies for pemphigus vulgaris.

Authors:  Xuming Mao; Aimee S Payne
Journal:  Curr Opin Investig Drugs       Date:  2008-05

4.  Thyrotropin receptor and CD40 mediate interleukin-8 expression in fibrocytes: implications for thyroid-associated ophthalmopathy (an American Ophthalmological Society thesis).

Authors:  Raymond S Douglas; Tünde Mester; Anna Ginter; Denise S Kim
Journal:  Trans Am Ophthalmol Soc       Date:  2014

Review 5.  The Immunogenetics of Autoimmune Blistering Diseases.

Authors:  Diana Kneiber; Eric H Kowalski; Kyle T Amber
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 6.  Immunotherapy for Pemphigus: Present and Future.

Authors:  Huijie Yuan; Meng Pan; Hongxiang Chen; Xuming Mao
Journal:  Front Med (Lausanne)       Date:  2022-06-15

7.  Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-κB.

Authors:  Erin F Gillespie; Nupur Raychaudhuri; Konstantinos I Papageorgiou; Stephen J Atkins; Ying Lu; Laya K Charara; Tünde Mester; Terry J Smith; Raymond S Douglas
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-21       Impact factor: 4.799

Review 8.  Immune response in pemphigus and beyond: progresses and emerging concepts.

Authors:  Giovanni Di Zenzo; Kyle T Amber; Beyza S Sayar; Eliane J Müller; Luca Borradori
Journal:  Semin Immunopathol       Date:  2015-11-23       Impact factor: 9.623

9.  Transient anti-CD40L co-stimulation blockade prevents immune responses against human bullous pemphigoid antigen 2: implications for gene therapy.

Authors:  Christoph M Lanschuetzer; Edit B Olasz; Zelmira Lazarova; Kim B Yancey
Journal:  J Invest Dermatol       Date:  2008-11-27       Impact factor: 8.551

Review 10.  Pemphigus autoimmunity: hypotheses and realities.

Authors:  Sergei A Grando
Journal:  Autoimmunity       Date:  2011-09-23       Impact factor: 2.815

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.